Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of Donanemab Versus Placebo in Chinese Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease

NCT07571161 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT07571161
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07571161 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of Donanemab Versus Placebo in Chinese Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Recruiting
Start date
April 30, 2026
Completion date
April 30, 2030
Enrollment
140 (estimated)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease